Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D B Duggan

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Hematological Oncology|March 1, 1990
Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)K W Zamkoff, N P Watman, D B Duggan, et al.
American Journal of Clinical Pathology|April 1, 1991
Immunophenotyping of non-Hodgkin's lymphomas in paraffin-embedded tissue sections. A comparison with genotypic analysisM T Elghetany, A S Kurec, K Schuehler, et al.
Breast Cancer Research and Treatment|January 1, 1995
High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB)J J Perry, D A Berry, R B Weiss, et al.
Investigational New Drugs|January 1, 1994
A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) studyR B Weiss, B L Peterson, S L Allen, et al.
Cancer|July 1, 1993
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B studyS L Graziano, J E Herndon, F Richards, et al.
Clinical Immunology and Immunopathology|December 1, 1988
Polyspecificity of human monoclonal antibodies reactive with Mycobacterium leprae, mitochondria, ssDNA, cytoskeletal proteins, and the acetylcholine receptorD B Duggan, C Mackworth-Young, A Kari-Lefvert, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1997
Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's diseaseC T Chung, J A Bogart, J F Adams, et al.
Blood|April 1, 1988
HTLV-I-induced lymphoma mimicking Hodgkin's disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNAD B Duggan, G D Ehrlich, F P Davey, et al.
Breast Cancer Research and Treatment|February 29, 2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)G G Kimmick, C Cirrincione, D B Duggan, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1992
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group BD B Duggan, M T Santarelli, K Zamkoff, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Hematological Oncology|March 1, 1990
Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)K W Zamkoff, N P Watman, D B Duggan, et al.
American Journal of Clinical Pathology|April 1, 1991
Immunophenotyping of non-Hodgkin's lymphomas in paraffin-embedded tissue sections. A comparison with genotypic analysisM T Elghetany, A S Kurec, K Schuehler, et al.
Breast Cancer Research and Treatment|January 1, 1995
High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB)J J Perry, D A Berry, R B Weiss, et al.
Investigational New Drugs|January 1, 1994
A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) studyR B Weiss, B L Peterson, S L Allen, et al.
Cancer|July 1, 1993
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B studyS L Graziano, J E Herndon, F Richards, et al.
Clinical Immunology and Immunopathology|December 1, 1988
Polyspecificity of human monoclonal antibodies reactive with Mycobacterium leprae, mitochondria, ssDNA, cytoskeletal proteins, and the acetylcholine receptorD B Duggan, C Mackworth-Young, A Kari-Lefvert, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1997
Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's diseaseC T Chung, J A Bogart, J F Adams, et al.
Blood|April 1, 1988
HTLV-I-induced lymphoma mimicking Hodgkin's disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNAD B Duggan, G D Ehrlich, F P Davey, et al.
Breast Cancer Research and Treatment|February 29, 2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)G G Kimmick, C Cirrincione, D B Duggan, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1992
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group BD B Duggan, M T Santarelli, K Zamkoff, et al.
Pageof 3